New approaches for the treatment of refractory meningiomas

Cancer Control

Volumn 10, Issue 2, 2003, Pages 148-158

  Ragel, Brian ^a   Jensen, Randy L ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; ADENOVIRUS VECTOR; ALPHA INTERFERON; ALPHA2B INTERFERON; ANGIOGENESIS INHIBITOR; BROMOCRIPTINE; CALCIUM CHANNEL BLOCKING AGENT; CARMUSTINE; FUMAGILLOL CHLOROACETYLCARBAMATE; GENE PRODUCT; HYDROXYUREA; KI 67 ANTIGEN; MERLIN; MIFEPRISTONE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NF2 TRANSGENE; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; SURAMIN; TRAPIDIL; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VERAPAMIL; VEROTOXIN;

ANTIBODY LABELING; ANTINEOPLASTIC ACTIVITY; BEAM THERAPY; BRAIN SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CELL GROWTH; CLINICAL TRIAL; DRUG MECHANISM; GENE THERAPY; GENETIC TRANSDUCTION; GROWTH INHIBITION; HERPES SIMPLEX VIRUS; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MENINGIOMA; NONHUMAN; RADIOSURGERY; REVIEW; SIGNAL TRANSDUCTION; STEREOTAXIC SURGERY; TRANSGENE; TUMOR CELL; TUMOR LOCALIZATION; TUMOR RECURRENCE; VIRUS GENE; VIRUS RECOMBINANT;

EID: 0037358039     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480301000206     Document Type: Review

References (78)

1. Carroll RS, Zhang J, Black PM. Expression of estrogen receptors alpha and beta in human meningiomas. J Neurooncol. 1999;42:109-116.
2. Gonzales MF. Classification of brain tumors. In: Kaye AH, Laws ER, eds. Brain Tumors: An Encyclopedic Approach. Edinburgh, New York: Churchill Livingstone; 1995:675.
3. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957;20:22-39.
4. Mirimanoff RO, Dosoretz DE, Linggood RM, et al. Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg. 1985;62:18-24.
5. Mahmood A, Caccamo DV, Tomecek FJ, et al. Atypical and malignant meningiomas: a clinicopathological review. Neurosurgery. 1993;33:955-963.
6. Jaaskelainen J, Haltia M, Servo A. Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol. 1986;25:233-242.
7. Milosevic MF, Frost PJ, Laperriere NJ, et al. Radiotherapy for atypical or malignant intracranial meningioma. Intl J Radiat Oncol Biol Phys. 1996;34:817-822.
8. Goldsmith BJ, Wara WM, Wilson CB, et al. Postoperative irradiation for subtotally resected meningiomas: a retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg. 1994;80:195-201.
9. Rosenthal MA, Ashley DL, Cher L. Treatment of high risk or recurrent meningiomas with hydroxyurea. J Clin Neurosci. 2002;9:156-158.
10. Hug EB, Devries A, Thornton AF, et al. Management of atypical and malignant meningiomas: role of high-dose, 3D-conformal radiation therapy. J Neurooncol. 2000;48:151-160.
11. Barnett GH, Suh JH, Crownover RL. Recent advances in the treatment of skull base tumors using radiation. Neurosurg Clin N Am. 2000;11:587-596.
12. Schrell UM, Rittig MG, Anders M. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg. 1997;86:840-844.
13. Mason WP, Gentili F, Macdonald DR, et al. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg. 2002;97:341-346.
14. Blankenstein MA, Verheijen FM, Jacobs JM, et al. Occurrence, regulation, and significance of progesterone receptors in human meningioma. Steroids. 2000;65:795-800.
15. Cohen ME, Duffner PK. Long-term consequences of CNS treatment for childhood cancer, Part I: Pathologic consequences and potential for oncogenesis. Pediatr Neurol. 1991;7:157-163.
16. Shintani T, Hayakawa N, Hoshi M, et al. High incidence of meningioma among Hiroshima atomic bomb survivors. Radiat Res (Tokyo). 1999;40:49-57.
17. Evans DG, Sainio M, Baser ME. Neurofibromatosis type 2. J Med Genet. 2000;37:897-904.
18. Cai DX, Banerjee R, Scheithauer BW, et al. Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: diagnostic and prognostic implications. J Neuropathol Exp Neurol. 2001;60:628-636.
19. Bostrom J, Meyer-Puttlitz B,Wolter M, et al. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18CINK4c)) in atypical and anaplastic meningiomas. Am J Pathol. 2001;159:661-669.
20. Lopez-Gines C, Cerda-Nicolas M, Gil-Benso R, et al. Loss of 1p in recurrent meningiomas. A comparative study in successive recurrences by cytogenetics and fluorescence in situ hybridization. Cancer Genet Cytogenet. 2001;125:119-124.
21. Nakasu S, Li DH, Okabe H, et al. Significance of MIB-1 staining indices in meningiomas: comparison of two counting methods. Am J Surg Pathol. 2001;25:472-478.
22. Ho DM, Hsu CY, Ting LT, et al. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma. Cancer. 2002;94:1538-1547.
23. Lanzafame S, Torrisi A, Barbagallo G, et al. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up. Pathol Res Pract. 2000;196:483-488.
24. Korshunov A, Shishkina L, Golanov A. DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases. Arch Pathol Lab Med. 2002;126:1079-1086.
25. Perry A, Stafford SL, Scheithauer BW, et al. The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer. 1998;82:2262-2269.
26. Kamei Y, Watanabe M, Nakayama K, et al. Prognostic significance of p53 and p21WAF1/CIP1 immunoreactivity and tumor micronecrosis for recurrence of meningiomas. J Neurooncol. 2000;46:205-213.
27. Abramovich CM, Prayson RA. Apoptotic activity and bcl-2 immunoreactivity in meningiomas. Association with grade and outcome. Am J Clin Pathol. 2000;114:84-92.
28. Comtesse N, Heckel D, Racz A, et al. Five novel immunogenic antigens in meningioma: cloning, expression analysis, and chromosomal mapping. Clin Cancer Res. 1999;5:3560-3568.
29. Weisberg S, Ashkenazi E, Israel Z, et al. Anaplastic and atypical meningiomas express high levels of Fas and undergo apoptosis in response to Fas ligation. Am J Pathol. 2001;159:1193-1197.
30. Kilic T, Bayri Y, Ozduman K, et al. Tenascin in meningioma: expression is correlated with anaplasia, vascular endothelial growth factor expression, and peritumoral edema but not with tumor border shape. Neurosurgery. 2002;51:183-193.
31. Miralbell R, Lingood RM, de la Monte S, et al. The role of radiotherapy in the treatment of subtotally resected benign meningiomas. J Neurooncol. 1992;13:157-164.
32. Barbaro NM, Gutin PH, Wilson CB, et al. Radiation therapy in the treatment of partially resected meningiomas. Neurosurgery. 1987;20:525-528.
33. Lee JY, Niranjan A, McInerney J, et al. Stereotactic radiosurgery providing long-term tumor control of cavernous sinus meningiomas. J Neurosurg. 2002;97:65-72.
34. Sartor O, Figg WD. Mifepristone: antineoplastic studies. Clin Obstet Gynecol. 1996;39:498-505.
35. Olson JJ, Beck DW, Schlechte J, et al. Hormonal manipulation of meningiomas in vitro. J Neurosurg. 1986;65:99-107.
36. Matsuda Y, Kawamoto K, Kiya K, et al. Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo. J Neurosurg. 1994;80:527-534.
37. Olson JJ, Beck DW, Schlechte JA, et al. Effect of the antiprog-esterone RU-38486 on meningioma implanted into nude mice. J Neurosurg. 1987;66:584-587.
38. Koper JW, Foekens JA, Braakman R, et al. Effects of progesterone on the response to epidermal growth factor and other growth factors in cultured human meningioma cells. Cancer Res. 1990;50:2604-2607.
39. Grunberg SM, Weiss MH, Spitz IM, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg. 1991;74:861-866.
40. Grunberg SM. Role of antiprogestational therapy for meningiomas. Human Reprod. 1994;9(suppl 1):202-207.
41. Lamberts SW, Tanghe HL, Avezaat CJ, et al. Mifepristone (RU 486) treatment of meningiomas. J Neurol Neurosurg Psychiatry. 1992;55:486-490.
42. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-364.
43. Folkman J, Ingber D. Inhibition of angiogenesis. Semin Cancer Biol. 1992;3:89-96.
44. Kaba SE, De Monte F, Bruner JM et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery. 1997;40:271-275.
45. Koper JW, Zwarthoff EC, Hagemeijer A, et al. Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha. Eur J Cancer. 1991;27:416-419.
46. Zhang ZJ, Muhr C, Wang JL. Interferon-alpha inhibits the DNA synthesis induced by PDGF and EGF in cultured meningioma cells. Anticancer Res. 1996;16:717-723.
47. Wober-Bingol C, Wober C, Marosi C, et al. Interferon-alfa-2b for meningioma. Lancet. 1995;345:331.
48. Muhr C, Gudjonsson O, Lilja A, et al. Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography. Clin Cancer Res. 2001;7:2269-2276.
49. Yazaki T, Takamiya Y, Castello PC, et al. Inhibition of angiogenesis and growth of human non-malignant and malignant meningiomas by TNP-470. J Neurooncol. 1995;23:23-29.
50. Bek EL, McMillen MA. Endothelins are angiogenic. J Cardiovasc Pharmacol. 2000;36(5 suppl 1):S135-S139.
51. Harland SP, Kuc RE, Pickard JD, et al. Expression of endothelin(A) receptors in human gliomas and meningiomas, with high affinity for the selective antagonist PD156707. Neurosurgery. 1998;43:890-899.
52. Salhia B, Rutka JT, Lingewood C, et al. The treatment of malignant meningioma with verotoxin. Neoplasia. 2002;4:304-311.
53. Lawrence JH, Tobias CA, Linfoot JA, et al. Successful treatment of acromegaly: metabolic and clinical studies in 145 patients. J Clin Endocrinol Metab. 1970;31:180-198.
54. Khandwala HM, McCutcheon IE, Flyvbjerg A, et al. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev. 2000;21:215-244.
55. Friend KE. Cancer and the potential place for growth hormone receptor antagonist therapy. Growth Horm IGF Res. 2001;11(suppl A)S121-S123.
56. McCutcheon IE, Flyvbjerg A, Hill H, et al. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg. 2001;94:487-492.
57. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342:1171-1177.
58. van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358:1754-1759.
59. Garcia-Luna PP, Relimpio F, Pumar A, et al. Clinical use of octreotide in unresectable meningiomas: a report of three cases. J Neurosurg Sci. 1993;37:237-241.
60. Schulz S, Pauli SU, Schulz S, et al. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res. 2000;6:1865-1874.
61. Schrell UM, Gauer S, Kieswetter F, et al. Inhibition of proliferation of human cerebral meningioma cells by suramin: effects on cell growth, cell cycle phases, extracellular growth factors, and PDGF-BB autocrine growth loop. J Neurosurg. 1995;82:600-607.
62. Todo T E, Adams F, Fahlbusch R. Inhibitory effect of trapidil on human meningioma cell proliferation via interruption of autocrine growth stimulation. J Neurosurg. 1993;78:463-469.
63. Jensen RL, Lee YS, Guijrati M, et al. Inhibition of in vitro meningioma proliferation after growth factor stimulation by calcium channel antagonists, Part II: Additional growth factors, growth factor receptor immunohistochemistry, and intracellular calcium measurements. Neurosurgery. 1995;37:937-947.
64. Jensen RL, Origitano TC, Lee YS, et al. In vitro growth inhibition of growth factor-stimulated meningioma cells by calcium channel antagonists. Neurosurgery. 1995;36:365-374.
65. Jensen RL, Petr M, Wurster RD. Calcium channel antagonist effect on in vitro meningioma signal transduction pathways after growth factor stimulation. Neurosurgery. 2000;46:692-703.
66. Merry S, Fetherston CA, Kaye SB, et al. Resistance of human glioma to adriamycin in vitro: the role of membrane transport and its circumvention with verapamil. Br J Cancer. 1986;53:129-135.
67. Jensen RL, Leppla D, Rokosz N, et al. Matrigel augments xenograft transplantation of meningioma cells into athymic mice. Neurosurgery. 1998;42:130-136.
68. Jensen RL Wurster RD. Calcium channel antagonists inhibit growth of subcutaneous xenograft meningiomas in nude mice. Surg Neurol. 2001;55:275-283.
69. Bowles AP Jr, Pantazis CG, Wansley W. Use of verapamil to enhance the antiproliferative activity of BCNU in human glioma cells: an in vitro and in vivo study. J Neurosurg. 1990;73:248-253.
70. Cano-Gauci DF, Riordan JR. Action of calcium antagonists on multidrug resistant cells: specific cytotoxicity independent of increased cancer drug accumulation. Biochem Pharmacol. 1987;36:2115-2123.
71. Helson L. Calcium channel blocker enhancement of anticancer drug cytotoxicity: a review. Cancer Drug Deliv. 1984;1:353-361.
72. Ince P, Appleton DR, Finney KH, et al. Verapamil increases the sensitivity of primary human colorectal carcinoma tissue to vincristine. Br J Cancer. 1986;53:137-139.
73. Robinson BA, Clutterbuck RD, Millar JL, et al. Verapamil potentiation of melphalan cytotoxicity and cellular uptake in murine fibrosarcoma and bone marrow. Br J Cancer. 1985;52:813-822.
74. Tsuruo T, Iida H, Tsukagoshi S, et al. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981;41:1967-1972.
75. Johnson MD, Woodard A, Kim P, et al. Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells. J Neurosurg. 2001;94:293-300.
76. Chauvet AE, Kesava PP, Goh CS, et al. Selective intraarterial gene delivery into a canine meningioma. J Neurosurg. 1998;88:870-873.
77. Ikeda K, Saeki Y, Gonzalez-Agosti C, et al. Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer. J Neurosurg. 1999;91:85-92.
78. Dirven CM, Grill J, Lamfers ML, et al. Gene therapy for meningioma: improved gene delivery with targeted adenoviruses. J Neurosurg. 2002;97:441-449.